Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heat-stable carbetocin for treatment of postpartum haemorrhage
PACTR202409528247888Phase 3Not yet recruiting
- Sponsor
- World Health Organization
- Start
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 3
01
Overview
Phase 3, randomised trial in postpartum hemorrhage (PPH) comparing Heat-stable carbetocin with Oxytocin (2 arms). Primary endpoint: Additional blood loss of 500 mL or more. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
heat-stable carbetocinoxytocin
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on PACTR202409528247888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202409528247888.